甲氨蝶呤联合ICE方案治疗弥漫大B细胞淋巴瘤的疗效及生存分析

摘要/Abstract

摘要： 目的：研究甲氨蝶呤联合ICE方案(异环磷酰胺、依托泊苷、卡铂)治疗弥漫大B细胞淋巴瘤(DLBCL)的疗效及生存情况。方法：选取2020年9月至2021年9月于我院治疗的110例DLBCL患者作为研究对象，实施回顾性分析，根据治疗方式的不同分为观察组(66例，甲氨蝶呤联合ICE方案治疗)和对照组(44例，ICE方案治疗)。比较两组患者临床疗效、生化指标、并发症发生情况和生存情况。结果：观察组患者肿瘤控制率高于对照组(P<0.05)。治疗后，观察组患者血管内皮生长因子(VEGF)、β2微球蛋白(β2-MG)、乳酸脱氢酶 (LDH)、糖类抗原125(CA125)水平均低于对照组，且以上各指标均呈正相关关系(P<0.05)。两组患者并发症种类数差异无统计学意义(P>0.05)。观察组患者生存期大于9个月的比例高于对照组(P<0.05)。影响患者生存期的因素有分组(治疗方法)、骨髓侵犯、国际预后指数(IPI指数)、年龄、体质量指数(BMI)、病灶数、VEGF。结论：甲氨蝶呤联合ICE方案治疗DLBCL有效，可改善患者临床癌症指标，延长患者生存期。

关键词: font-size:medium, ">甲氨蝶呤；ICE方案；弥漫大B细胞淋巴瘤；疗效；生存

Abstract: Objective：To study the efficacy and survival of methotrexate combined with ICE regimen(ifosfamide， etoposide，carboplatin) in the treatment of diffuse large B-cell lymphoma (DLBCL). Methods：110 DLBCL patients admitted in our hospital from September 2020 to September 2021were selected as the research objects for retrospective analysis，and were divided into the observation group (66 cases， methotrexate combined ICE regimen treatment) and the control group (44 cases，ICE regimen treatment)according to different treatment methods. The clinical efficacy， biochemical indexes， complications and survival of the two groups of patients were compared. Results：The tumor control rate of the observation group was higher than that of the control group (P<0.05). After treatment， the levels of VEGF， β2-MG， LDH and CA125 of patients in the observation group were lower than those in the control group， and there was a positive correlation between the above indicators (P<0.05). There was no statistical difference in the number of complications between the two groups (P>0.05). The proportion of patients with survival longer than 9 months in the observation group was higher than that of the controlgroup (P<0.05). The factors influencing the survival of patients were grouping (treatment method)， bone marrow invasion， IPI index， age， BMI， number of lesions and VEGF. Conclusion：Methotrexate combined with ICE regimen is effective in the treatment of DLBCL，which can improve the clinical cancer indicators and prolong the survival of patients.

Key words: font-size:medium, ">Methotrexate； ICE regimen； Diffuse large B-cell lymphoma； Efficacy；Survival

中图分类号:

李新涛, 申兴勇, 刘爽, 刘逸之. 甲氨蝶呤联合ICE方案治疗弥漫大B细胞淋巴瘤的疗效及生存分析[J]. 中国医药导刊, 2022, 24(12): 1204-1210.

LI Xintao, SHEN Xingyong, LIU Shuang, LIU Yizhi. Efficacy and Survival Analysis of Methotrexate Combined with ICE Regimen in the Treatment of Diffuse Large B-Cell Lymphoma[J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2022, 24(12): 1204-1210.

参考文献

[1]Papageorgiou SG， Thomopoulos TP， Katagas I， et al. Prognostic molecular biomarkers in diffuse large B-cell lymphoma in the rituximab era and their therapeutic implications[J]. Ther Adv Hematol，2021，12：1-26.
     [2]Lodhi N， Tun M， Nagpal P， et al. Biomarkers and novel therapeutic approaches for diffuse large B-cell lymphoma in the era of precision medicine[J]. Oncotarget， 2020，11(44)：4045-4073.
     [3]Di M， Huntington SF， Olszewski AJ. Challenges and opportunities in the management of diffuse large B-cell lymphoma in older patients[J]. Oncologist，2021，26(2)：120-132.
     [4]Roschewski M， Phelan JD， Wilson WH. Molecular classification and treatment of diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma[J]. Cancer J，2020，26(3)：195-205.
     [5]Cioroianu AI， Stinga PI， Sticlaru L， et al. Tumor microenvironment in diffuse large B-cell lymphoma：role and prognosis[J]. Anal Cell Pathol (Amst)，2019，2019：1-9.
     [6]Jelicic J， Larsen TS， Frederiksen H， et al. Statistical challenges in development of prognostic models in diffuse large B-cell lymphoma：comparison between existing models-a systematic review[J]. Clin Epidemiol， 2020，12：537-555.
     [7]Lodhi N， Tun M， Nagpal P， et al. Biomarkers and novel therapeutic approaches for diffuse large B-cell lymphoma in the era of precision medicine[J]. Oncotarget，2020，11(44)：4045-4073.
     [8]Di M， Huntington SF， Olszewski AJ. Challenges and opportunities in the management of diffuse large B-cell lymphoma in older patients[J]. Oncologist，2021，26(2)：120-132.
     [9]Nowakowski GS， Hong F， Scott DW， et al. Addition of lenalidomide to R-CHOP improves outcomes in newly diagnosed diffuse large B-cell lymphoma in a randomized phase IIUS intergroup study ECOG-ACRIN E1412[J]. J Clin Oncol， 2021， 39(12)：1329-1338.
     [10]Danilov AV， Magagnoli M， Matasar MJ. Translating the biology of diffuse large B-cell lymphoma into treatment[J]. Oncologist，2022，27(1)：57-66.
     [11]Zheng Y， Si J， Yuan T， et al. Immune targeted therapy for diffuse large B cell lymphoma[J]. Blood Sci， 2021， 3(4)：136-148.
     [12]Alame M， Cornillot E， Cacheux V， et al. The immune contexture of primary central nervous system diffuse large B cell lymphoma associates with patient survival and specific cell signaling[J]. Theranostics，2021，11(8)：3565-3579.
     [13]Chen H， Zhong Q， Zhou Y， et al. Enhancement of the international prognostic index with β2-microglobulin， platelet count and red blood cell distribution width： a new prognostic model for diffuse large B-cell lymphoma in the rituximab era[J]. BMC Cancer，2022，22(1)：583.
     [14]Koch K， Richter J， Hanel C， et al. Follicular lymphoma grade 3B and diffuse large B-cell lymphoma present a histopathological and molecular continuum lacking features of progression/ transformation[J]. Haematologica，2022，107(9)：2144-2153.
     [15]刘爱宁，李媛媛，刘婷婷，等. 弥漫大B细胞淋巴瘤患者血清肿瘤负荷相关指标与临床分期、治疗效果及临床预后的关系[J]. 疑难病杂志，2020，19(11)：1119-1124.
     [16]杨晓刚，盛赠美，朱秋良. ICE方案联合甲氨蝶呤对弥漫大B细胞淋巴瘤患者的临床疗效及miR-451a、miR-15a表达的影响[J]. 中国医师杂志，2021，23(5)：720-724.
     [17]孙阳阳，耿翔，周晓莉，等. 原发性胃弥漫大B细胞淋巴瘤临床病理学观察及预后因素分析[J]. 中国癌症杂志，2019，29(9)：715-722.
     [18]齐瑞丽，邱鸣寒，张廷，等. 复发/难治性弥漫大B细胞淋巴瘤的治疗进展[J]. 临床肿瘤学杂志，2022，27(8)：758-763.
     [19]高弘烨，朱军. 老年弥漫大B细胞淋巴瘤一线治疗进展[J]. 中国现代医学杂志，2022，32(14)：53-60.
     [20]陈婷婷，张新友，周继豪. 弥漫大B细胞淋巴瘤的临床及分子分型研究进展[J]. 广东医学，2022，43(2)：156-161.

快速检索引用检索图表检索高级检索